333 filings
Page 11 of 17
8-K/A
ymg925hb
21 Jul 20
Other Events
12:00am
8-K
tvfo6ohdl7topa1t
20 Jul 20
INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
1:24pm
424B5
1c4mbq i3
16 Jul 20
Prospectus supplement for primary offering
2:14pm
8-K
2j76ei5zkg o4e3lq77
16 Jul 20
INmune Bio, Inc. Prices Public Offering of Common Stock
9:27am
424B5
i8ox wh888fx0
15 Jul 20
Prospectus supplement for primary offering
4:52pm
8-K
3uk7sw
13 Jul 20
Other Events
4:18pm
8-K
2rzfy1jr31wm4qha
10 Jul 20
INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer’s Disease Prior to Start of AAIC 2020
4:01pm
8-K
j9u 5j0wqjfaw2wk
15 Jun 20
INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS
4:08pm
8-K
29s hpgnxhk
20 May 20
Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer
4:16pm
8-K
brf42y2m7 5c
18 May 20
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION May 2020
6:21am
8-K
yxlwuoddeh
15 May 20
INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update
9:06am
8-K
zorod6w 5hm
12 May 20
Other Events
5:14pm
8-K
p1q20sm
7 May 20
INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call
4:06pm
8-K
twffdn2
5 May 20
Other Events
9:01am
8-K
0qiw1b
28 Apr 20
Other Events
5:03pm
424B3
j8518jti7nzu9a
24 Apr 20
Prospectus supplement
4:05pm
8-K
8bmx0
23 Apr 20
Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer
4:03pm
8-K
etonkz4
22 Apr 20
INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells
4:01pm
8-K
av07xcl2z8 8igr91we
21 Apr 20
Other Events
4:10pm